EGFR and glioblastoma: In GBM, the specific gain-of-function mutation of EGFR, and more specifically the constitutive activation of EGRF variant type III (EGFRvIII), is considered as a driver mutation to activate the MAPK/ERK pathway which consequently leads to tumorigenesis [155,156,157].